Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition
dc.contributor.author | Dimitriu, T | |
dc.contributor.author | Kurilovich, E | |
dc.contributor.author | Łapińska, U | |
dc.contributor.author | Severinov, K | |
dc.contributor.author | Pagliara, S | |
dc.contributor.author | Szczelkun, MD | |
dc.contributor.author | Westra, ER | |
dc.date.accessioned | 2022-02-08T15:01:39Z | |
dc.date.issued | 2021-12-20 | |
dc.date.updated | 2022-02-08T14:30:08Z | |
dc.description.abstract | Phages impose strong selection on bacteria to evolve resistance against viral predation. Bacteria can rapidly evolve phage resistance via receptor mutation or using their CRISPR-Cas adaptive immune systems. Acquisition of CRISPR immunity relies on the insertion of a phage-derived sequence into CRISPR arrays in the bacterial genome. Using Pseudomonas aeruginosa and its phage DMS3vir as a model, we demonstrate that conditions that reduce bacterial growth rates, such as exposure to bacteriostatic antibiotics (which inhibit cell growth without killing), promote the evolution of CRISPR immunity. We demonstrate that this is due to slower phage development under these conditions, which provides more time for cells to acquire phage-derived sequences and mount an immune response. Our data reveal that the speed of phage development is a key determinant of the evolution of CRISPR immunity and suggest that use of bacteriostatic antibiotics can trigger elevated levels of CRISPR immunity in human-associated and natural environments. | en_GB |
dc.description.sponsorship | European Union Horizon 2020 | en_GB |
dc.description.sponsorship | Natural Environment Research Council (NERC) | en_GB |
dc.description.sponsorship | Ministry of Science and Higher Education of the Russian Federation | en_GB |
dc.description.sponsorship | National Institutes of Health (NIH) | en_GB |
dc.description.sponsorship | Russian Science Foundation | en_GB |
dc.format.extent | 31-40.e5 | |
dc.format.medium | Print-Electronic | |
dc.identifier.citation | Vol. 30(1), pp. 31–40.e1–e5 | en_GB |
dc.identifier.doi | https://doi.org/10.1016/j.chom.2021.11.014 | |
dc.identifier.grantnumber | ERC-2017-ADG-788405 | en_GB |
dc.identifier.grantnumber | ERC-STG-2016-714478 | en_GB |
dc.identifier.grantnumber | NE/M018350/1 | en_GB |
dc.identifier.grantnumber | 075-15-2019-1661 | en_GB |
dc.identifier.grantnumber | RO1 10407 | en_GB |
dc.identifier.grantnumber | 19-74-20130 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/128734 | |
dc.identifier | ORCID: 0000-0002-1604-2622 (Dimitriu, Tatiana) | |
dc.identifier | ORCID: 0000-0001-9796-1956 (Pagliara, Stefano) | |
dc.identifier | ORCID: 0000-0003-4396-0354 (Westra, Edze R) | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier (Cell Press) | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/34932986 | en_GB |
dc.relation.url | https://doi.org/10.17632/gbdfwg325y.1 | en_GB |
dc.rights | © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en_GB |
dc.subject | CRISPR-Cas immunity | en_GB |
dc.subject | antibiotics | en_GB |
dc.subject | growth rate | en_GB |
dc.subject | phage therapy | en_GB |
dc.subject | spacer acquisition | en_GB |
dc.title | Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-02-08T15:01:39Z | |
dc.identifier.issn | 1931-3128 | |
exeter.place-of-publication | United States | |
dc.description | This is the final version. Available on open access from Cell Press via the DOI in this record | en_GB |
dc.description | Data and code availability: Source data are available at Mendeley Data: https://doi.org/10.17632/gbdfwg325y.1 This paper does not report original code. Any additional information required to reanalyse the data reported in this paper is available from the lead contact upon request. | en_GB |
dc.identifier.eissn | 1934-6069 | |
dc.identifier.journal | Cell Host Microbe | en_GB |
dc.relation.ispartof | Cell Host Microbe, 30(1) | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2021-11-24 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-12-20 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-02-08T14:57:55Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-02-08T15:03:52Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).